Oregon Drug Use Review / Pharmacy & Therapeutics Committee
Thursday, December 1st, 2022 1:00 - 5:00 PM
Remote Meeting via Zoom Platform

MEETING AGENDA

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333.

I. CALL TO ORDER

1:00 PM
A. Roll Call & Introductions R. Citron (OSU)
B. Conflict of Interest Declaration R. Citron (OSU)
C. Approval of Agenda R. Citron (OSU)
D. Approval of Minutes R. Citron (OSU)
E. Department Update A. Gibler (OHA)

II. CONSENT AGENDA TOPICS

1:20 PM
A. Quarterly Utilization Reports S. Ramirez (Chair)
B. Oncology Prior Authorization Updates
C. Orphan Drug Policy Updates
   1. Public Comment

III. DUR ACTIVITIES

1:25 PM
A. ProDUR Report L. Starkweather (Gainwell)
B. RetroDUR Report D. Engen (OSU)
C. Oregon State Drug Review K. Sentena (OSU)
   1. Asthma Guidance Update with a Focus on Changes for Managing Patients with Mild Asthma
   2. Population Trends in the Use of Migraine Preventative Treatments

IV. DUR NEW BUSINESS

1:40 PM
A. Polypharmacy Drug Utilization Evaluation D. Engen (OSU)
   1. Drug Utilization Evaluation
   2. Public Comment
   3. Discussion and Clinical Recommendations to OHA
1:55 PM  
B. Early Periodic Screening Diagnosis and Treatment (EPSDT)  
   1. Prior Authorization Criteria  
   2. Public Comment  
   3. Discussion and Clinical Recommendations to OHA  

V. DUR OLD BUSINESS

2:20 PM  
A. Sedatives Prior Authorization Update  
   1. Prior Authorization Criteria  
   2. Public Comment  
   3. Discussion and Clinical Recommendations to OHA  

VI. PREFERRED DRUG LIST NEW BUSINESS

2:35 PM  
A. Growth Hormone Prior Authorization Update  
   1. Prior Authorization Criteria  
   2. Public Comment  
   3. Discussion and Clinical Recommendations to OHA  

2:50 PM  
BREAK

3:05 PM  
B. Drugs for Asthma/COPD Class Update  
   1. Class Update/Prior Authorization Criteria  
   2. Public Comment  
   3. Discussion and Clinical Recommendations to OHA  

3:20 PM  
C. Influenza Class Update  
   1. Class Update/Prior Authorization Criteria  
   2. Public Comment  
   3. Discussion and Clinical Recommendations to OHA  

3:40 PM  
D. Topical Products for Inflammatory Skin Conditions Class Update and New Drug Evaluations  
   1. Class Update/Prior Authorization Criteria  
   2. Zoryve™ (roflumilast cream) New Drug Evaluation  
   3. Vtama® (tapinarof cream) New Drug Evaluation  
   4. Public Comment  
   5. Discussion and Clinical Recommendations to OHA  

3:55 PM  
VII. EXECUTIVE SESSION

4:50 PM  
VIII. RECONVENE for PUBLIC RECOMMENDATIONS

IX. ADJOURN